The Role of Inflammation in Ocular Tumours
- Conditions
- Ocular Melanoma
- Registration Number
- NCT02909517
- Lead Sponsor
- Unity Health Toronto
- Brief Summary
This prospective, non-therapeutic study will determine whether a novel imaging technique can identify presumptive tumour associated macrophages (TAMs) in patients with ocular tumours.
The investigators will evaluate 5 groups:
1. Choroidal nevus
2. Choroidal indeterminate melanocytic lesion
3. Choroidal melanoma
4. Suspected metastatic tumour (ie, primary tumour elsewhere)
5. Locally treated ocular tumours
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Any tentative clinical diagnosis of:
- Choroidal nevus (low-risk features):
- Choroidal indeterminate melanocytic lesion (high-risk features)
- Choroidal melanoma
- Suspected metastatic tumour (ie, primary tumour elsewhere)
- Locally treated ocular tumours
Note that a patient can enroll in this study twice, once before treatment and once after, provided that at least one month has passed since initiation of treatment. This patient will count twice (ie, once in each of two study arms)
Male and female age 18 years and older Ability to provide informed consent
- Allergy to angiography dye
- Cases that do not meet the above criteria for tumor size will be ineligible to participate in the study.
- Patients not able to provide consent for the study.
- Patients with a poor view of the fundus due to cataract or vitreous hemorrhage.
- Patients < 18 years of age. Any concurrent unrelated eye diagnosis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of macrophages 1 week
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
St Michael's Hospital
🇨🇦Toronto, Ontario, Canada
Princess Margaret Cancer Centre, Ontario
🇨🇦Toronto, Ontario, Canada
St Michael's Hospital🇨🇦Toronto, Ontario, CanadaShelley Boyd, MDContact416-864-6060BoydS@smh.ca